Angle Plc has raised a further £2.8 million to complement a £12.2 million fundraising announced on 5 October. The monies will help the company finance the purchase of assets from Canada-based Axela Inc that will broaden its liquid biopsy capabilities enabling it to both harvest circulating tumour cells from patients and analyse them for gene expression.
Erytech Pharma SA has become the second European biotech in less than a week to propose a global public share offering including a listing on the US Nasdaq market. The French company notified the Securities and Exchange Commission on 6 October of plans to raise up to $100 million.
Netherlands-based Kiadis Pharma NV has called on investors for the second time since June, raising €18 million to support the development of its cell therapy platform for making bone marrow transplantations safer. The company placed 2.25 million new shares with investors.
Faron Pharmaceuticals Oy has raised £10 million, before expenses, in a private share placement to support the late-stage development and commercialisation of its product for acute respiratory distress syndrome Traumakine. Current and new investors supported the offering.
Angle Plc has raised £12.2 million, before expenses, to finance the purchase of assets from Canada-based Axela Inc that will broaden its liquid biopsy capabilities enabling it to both harvest circulating tumour cells from patients and analyse them for gene expression.
Finland-based Faron Pharmaceuticals Oy is proposing to raise up to £10 million, before expenses, in a private share placement to support the late-stage development and commercialisation of its product for acute respiratory distress syndrome Traumakine.
The British specialty pharma company BTG Plc has broadened its portfolio of treatments for hospital procedures with the acquisition of Roxwood Medical Inc of Redwood City, California. The deal is valued at up to $80 million.
Ablynx NV has filed registration documents with the US Securities and Exchange Commission to raise up to $150 million in an initial public offering of its shares on Nasdaq. Based in Ghent, Belgium, Ablynx went public on Euronext in Brussels in 2007.
Novartis has announced a new academic alliance to explore the proteome as a source of new drug leads for cancer and other serious diseases. The collaboration is with the University of California Berkeley, US.
Evotec AG has made a €15 million equity investment in Exscientia Ltd which is developing artificial intelligence technologies to aid drug discovery. The German company already has a research collaboration with Exscientia dating from 2016.